key: cord-0774481-7xnjfb1a
authors: Grieco, Teresa; Rossi, Alfredo; Maddalena, Patrizia; Sernicola, Alvise; Ambrosio, Luca; Fino, Pasquale; Gomes, Vito
title: COVID-19 infection and BNT162b2 vaccine triggering sarcoid-like lesions in the same patient Response to: Sarcoid-like reaction in a patient recovering from coronavirus disease 19 pneumonia
date: 2022-01-21
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.12.042
sha: 4cd6a4a7bbd32944586658280c9e1c9d0e4a8c18
doc_id: 774481
cord_uid: 7xnjfb1a

nan

reactivity to COVID-19 infection. 1 Since then, different types of COVID-19 vaccines have been 42 produced. Among these, BNT162b2 (Comirnaty®, Pfizer/BioNTech, New York, NY, USA) is an 43 mRNA vaccine encoding the RBD of SARS-CoV-2 spike protein. 2 We report a case of cutaneous 44 sarcoid-like granulomatous reaction in a COVID-19 patient, reactivated by the administration of 45 BNT162b2 vaccine.

A 73-year-old Caucasian woman presented to our attention in July 2021, complaining of painful skin lesions on her arms and legs.

Physical examination revealed erythematous-violaceous painful nodules distributed bilaterally and 49 asymmetrically on her arms and legs, suggesting erythema nodosum-like lesions (Fig. 1) . On 50 palpation these nodules were mobile, warm, tender and there was no appreciable lymphadenopathy. 

Sarcoid-like reaction 91 in a patient recovering from coronavirus disease 19 pneumonia

Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian 95 subjects: An observational study

vaccine BNT162b1 elicits human antibody and TH1 T cell responses

New onset of alopecia areata in a patient with SARS-CoV-2 infection: 104 Possible pathogenetic correlations?